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Abstract
An overview of the in vitro test results on several human tumour cell lines of several series of
organotin compounds synthesized at the Free University of Brussels VUB. Several compounds
exhibit excellent antitumour activities. In vivo screening also gave very promising results.
Antitumour activity of diorganotin 2,6-pyridinedicarboxylates
Organotin compounds that exhibit promising antitumour properties were synthesized and
characterized at the Free University of Brussels. We would like to summarize here the results that
have already been patented(I) and that may therefore be disclosed(2).
Fig. 1- X-Ray structure of ethylphenyl pyridine-2,6-dicarboxylate.H20 dimer, HCCI3 solvate(3)
A series of diorganotin 2,6-pyridinedicarboxylates, C5H3N(COO)2SnRR’, were prepared and
tested(4), with different groups R and R’ bound to tin.
The crystal structure of the ethylphenyltin derivative(3) is shown in fig. 1.
The most in vitro active compounds are the di-n-butyl ones: they are characterized by inhibition
doses ID50 of 60 and 106 ng/mL, respectively, against two human cancer cell lines, MCF-7, a breast
cancer, and WiDr, a colon carninoma(2). For cisplatin, the ID50 values obtained for the same tumour
cell lines are 850 and 624 ng/mL, respectively.
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Fig. 2: X-Ray structure of diethyltin bis(2-methylthio-3-pyridinecarboxylate)(5)
Fig. 3" X-Ray structure of the [diethyl(2-methylthio-3-pyridinecarboxylato)tin oxide] dimer(5)
Antitumour activity of diorganotin dicarboxylates
Diorganotin derivatives of substituted salicylic acids(2) were also synthesized. Here, two types of
compounds can be made depending on the molar ratio carboxylic acid:diorganotin oxide used.
When a 2:1 molar ratio is used, the expected diorganotin dicarboxylate is formed. The structure of
.diethyltin bis(2-methylthio-3-pyridinecarboxylate)(5) is shown in fig. 2.
The di-n-butyltin compounds are again the most active ones. For instance, di-n-butyltin bis(4-
hydroxy-3-methoxybenzoate) is characterized by ID50 values of 44 and 82 ng/mL against MCF-7
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and WiDr, respectively(5).
.-(6) Fig. 4: X-Ray structure of the hexamer of di-n-butyltin thiosalicy
Antitumour activity of bis[carboxylato(diorganotin)] oxides
When a 1:1 molar ratio is used, a dimer of a bis[carboxylato(diorganotin)] oxide is obtained. The
crystal structure of [diethyl(2-methylthio-3-pyridinecarboxylato)tin] oxide(5) is shown in fig. 3; this
compounds remains a dimer in CDCI3 solution.
Once more, the di-n-butyltin derivatives proved to be the most active ones, much more active than
cisplatin: the 1:1 condensation compound di-n-butyltin oxide with 5-methoxysalicylic acid, {[(5-
CH3OC6H3(OH)COO)(Bu2)Sn]20}2, for instance, is characterized by ID50 values of 29 and 122
ng/mL against MCF-7 and WiDr, respectively.
In contrast to 1:1 condensation compounds of diorganotin oxides with salicylic acid, that are in fact
dimeric distannoxanes in which the phenolic oxygen is not lost, di-n-butyltin thiosalicylate
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crystallizes as a hexamer(6) (see fig. 4) with tin-carboxylate and tin-sulphur bonds, but becomes
monomeric in polar solvents such as DMSO, ethanol or water, in which the drugs are administrated
to perform the anticancer screening.
Exceptionally high antitumour activity of triphenyltin carboxylates
Several series of organotin molecules were prepared that are as active as mitomycin C in vitro
against MCF-7 and WiDr. The first of these, that have recently been patented(I), are triphenyltin
carboxylates XYZC6H2COOSnPh3(7).
Several of them (like the 2-methoxybenzoate or the 5-methoxysalicylate), are characterized by ID50
values of ca. 15 ng/mL against both MCF-7 and WiDr.
Other series of organotin compounds were synthesized that were found more active than these last
ones but they have first to be patented before more can be disclosed about them.
In vivo activity of organotin compounds
The the toxicity profiles in vivo in mice and the antitumour activity in tumour-bearing mice were
screened(8) for five organotin compounds that were found especially active in vitro: triphenyltin 5-
sulfosalicylate (1), triphenyltin 5-aminosalicylate (2), triphenyltin 4-fluorobenzoate (3), tri-n-butyltin
2,6-difluorobenzoate (4) and di-n-butyltin bis(2,5-dihydroxybenzoate) (5).
In vivo (table), compound 1 was most toxic mainly through paralysis. At their maximum tolerated
dosis (MTD) for a single administration, compounds 1,2, 3 and 4 are inactive against murine colon
carcinoma Colon 26. At a single administration, compound 5 was the most active with a Test/Control
ratio (T/C) below 0.6 and Growth Delay Factor (GDF) above 1.0, their respective cut-off levels for
sensitivity.
Table: Antitumour effect of the tested compounds on Colon 26: Growth Delay Factor GDF, T/C
values, Tumour Doubling Time TDT, Median Life Span MLS and Increase inLife Span ILS
Treatment GDF T/C mean TDT MLS ILS
control
1,5 mg/kg 0.43 0.80 3.1 + 1.2
2,8 mg/kg 0.38 0.71 4.4 + 1.5
3,6 mg/kg 0.36 0.67 4.3 + 2.3
4,5 mg/kg 0.02 0.87 4.2 + 1.9
5,6 mg/kg 1.18 0.43 3.1 + 0.8
cisplatin, 5.5 mg/kg 0.18 0.73 5.9 + 1.5
cisplatin, 9 mg/kg 0.66 0.39 5.3 + 1.3
carboplatin, 90 mg/kg 1.00 0.52 5.8 + 1.6
20 100
22 111
20 100
22 111
22 111
22 111
GDF: Growth Delay Factor, indicates the tumour doubling time gained by treatment.
GDF (TDTtreated-TDTcontrol)TDTcontro
T/C: relative tumour volume treated mice/relative tumour volume control mice
MLS MedianLife Span
ILS Increase inLife Span (MLS treated mice)/(MLS untreated mice) x 100%.
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Conclusion
Many di- and triorganotin compounds have been found much more active than cis-platin in vitro
against two human tumour cell lines, MCF-7, a mammary tumour, and WiDr, a colon carcinoma.
In vivo test results show that di-n-butyltin bis(2,5-dihydroxybenzoate), compound ,5, is comparably
active to cisplatin at comparable doses. More work has however to be performed in order to find
organotin molecules that might become useful antitumour drugs in the future.
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